Výsledky vyhledávání - "Tania Ochi-Lohmann"

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Publikováno v: The Lancet Oncology. 20:924-937

Summary Background Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer and also showed clinical benefit when combined with ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9228908dbc590c8f16d533f8406c797a
https://doi.org/10.1016/s1470-2045(19)30167-6

Zobrazit plný text záznamu

Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC

Publikováno v: Cancer Research. 79:CT200-CT200

Background: Atezolizumab (atezo) (anti-PD-L1) monotherapy improves overall survival (OS) vs docetaxel in 2L+ NSCLC regardless of PD-L1 status; phase 3, 1L studies have shown clinical benefit of atezo plus chemotherapy and atezo in combination with be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::16e7aa0c549ed86cb11845e4d5e2750f
https://doi.org/10.1158/1538-7445.am2019-ct200

Zobrazit plný text záznamu

Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies

Autor: George Garibaldi, Henry A. Nasrallah, Rodrigo A. Bressan, Stephen R. Marder, Thomas Blaettler, Alice Wang, Stephen M. Lawrie, Dragana Bugarski-Kirola, Carol Reid, W. Wolfgang Fleischhacker, Julie Napieralski, Celso Arango, Mark Dixon, Tania Ochi-Lohmann

Publikováno v: Biological psychiatry. 82(1)

Background There is currently no standard of care for treatment of negative symptoms of schizophrenia, although some previous results with glutamatergic agonists have been promising. Methods Three (SunLyte [WN25308], DayLyte [WN25309], and FlashLyte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e534915ddd2dac61060e0ba54af0cd79
https://pubmed.ncbi.nlm.nih.gov/28619253

Zobrazit plný text záznamu

Mice presenting skeletal muscle hypertrophic phenotype driven by mIGF‐1 over‐expression have improved carbohydrate metabolism and insulin sensitivity

Autor: Maristela Mitiko Okamoto, Ubiratan Fabres Machado, Antonio O. Turri, Antonio Musarò, Anselmo Sigari Moriscot, Tania Ochi Lohmann, Monique de Oliveira-Costa, Marcelo A. Christoffolete, Miriam O. Ribeiro

Publikováno v: The FASEB Journal. 23

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f55819b14acaa104fe3bfdd235c569d8
https://doi.org/10.1096/fasebj.23.1_supplement.lb109

Zobrazit plný text záznamu

Efficacy and safety of adjunctive bitopertin (5 and 10mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the phase III DayLyte study

Autor: Stephen M. Lawrie, Alice Wang, Jon Luca Zhu, Henry A. Nasrallah, George Garibaldi, Dragana Bugarski-Kirola, Celso Arango, Tania Ochi Lohmann

Publikováno v: Schizophrenia Research. 158:e1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f923324525f62119417bca0afeba31a9
https://doi.org/10.1016/j.schres.2014.07.038

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání